vs
CRISPR Therapeutics AG（CRSP）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是CRISPR Therapeutics AG的1.6倍（$57.1M vs $35.7M），REGIS CORP净利率更高（0.8% vs -104.5%，领先105.3%），REGIS CORP同比增速更快（22.3% vs -82.3%），REGIS CORP自由现金流更多（$891.0K vs $-50.3M）
CRISPR Therapeutics AG是一家瑞美合资生物技术企业，总部位于瑞士楚格，在美国以CRISPR Therapeutics, Inc.名义开展业务。作为首批依托CRISPR基因编辑平台开发药物的企业之一，公司现有约500名员工，在瑞士楚格、美国波士顿、旧金山及英国伦敦设有办公点，专注于多种罕见病与常见病的治疗药物研发。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
CRSP vs RGS — 直观对比
营收规模更大
RGS
是对方的1.6倍
$35.7M
营收增速更快
RGS
高出104.5%
-82.3%
净利率更高
RGS
高出105.3%
-104.5%
自由现金流更多
RGS
多$51.2M
$-50.3M
损益表 — Q4 FY2024 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $35.7M | $57.1M |
| 净利润 | $-37.3M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -181.0% | 10.8% |
| 净利率 | -104.5% | 0.8% |
| 营收同比 | -82.3% | 22.3% |
| 净利润同比 | -141.8% | -94.0% |
| 每股收益（稀释后） | $-0.41 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRSPRGS
| Q4 25 | — | $57.1M | ||
| Q3 25 | — | $59.0M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | — | $57.0M | ||
| Q4 24 | $35.7M | $46.7M | ||
| Q3 24 | — | $46.1M | ||
| Q2 24 | — | $49.4M | ||
| Q1 24 | — | $49.2M |
净利润CRSPRGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $116.5M | ||
| Q1 25 | — | $250.0K | ||
| Q4 24 | $-37.3M | $7.6M | ||
| Q3 24 | — | $-853.0K | ||
| Q2 24 | — | $91.2M | ||
| Q1 24 | — | $-2.3M |
营业利润率CRSPRGS
| Q4 25 | — | 10.8% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | — | 12.1% | ||
| Q1 25 | — | 8.8% | ||
| Q4 24 | -181.0% | 11.8% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.3% |
净利率CRSPRGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 192.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | -104.5% | 16.4% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | 184.7% | ||
| Q1 24 | — | -4.7% |
每股收益（稀释后）CRSPRGS
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $43.67 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | $-0.41 | $2.71 | ||
| Q3 24 | — | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | — | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $1.9B | $188.7M |
| 总资产 | $2.2B | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资CRSPRGS
| Q4 25 | — | $18.4M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $13.3M | ||
| Q4 24 | $1.9B | $10.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.9M |
总债务CRSPRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益CRSPRGS
| Q4 25 | — | $188.7M | ||
| Q3 25 | — | $187.6M | ||
| Q2 25 | — | $185.6M | ||
| Q1 25 | — | $68.6M | ||
| Q4 24 | $1.9B | $66.7M | ||
| Q3 24 | — | $56.4M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $-35.8M |
总资产CRSPRGS
| Q4 25 | — | $588.3M | ||
| Q3 25 | — | $592.1M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $511.2M | ||
| Q4 24 | $2.2B | $530.1M | ||
| Q3 24 | — | $508.9M | ||
| Q2 24 | — | $530.5M | ||
| Q1 24 | — | $543.7M |
负债/权益比CRSPRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.0M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-50.3M | $891.0K |
| 自由现金流率自由现金流/营收 | -140.9% | 1.6% |
| 资本支出强度资本支出/营收 | 0.7% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-325.9M | $14.9M |
8季度趋势，按日历期对齐
经营现金流CRSPRGS
| Q4 25 | — | $1.7M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $6.2M | ||
| Q4 24 | $-50.0M | $2.1M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-277.0K |
自由现金流CRSPRGS
| Q4 25 | — | $891.0K | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $6.2M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | $-50.3M | $1.7M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率CRSPRGS
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 10.3% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | -140.9% | 3.6% | ||
| Q3 24 | — | -3.0% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度CRSPRGS
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 0.7% | 0.9% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
现金转化率CRSPRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
